LDL/HDL ratio association with out-patient NIHSS score and Dyslipidemic Drug intake status as Metabolic Syndrome Criteria of ischemic stroke patients at RSUP Dr. Sardjito, Yogyakarta

Abstract

LDL-C/HDL-C ratio (numeric) is a more significant predictor of the progression of IMT than LDL-C or HDL-C alone (2). The Objective is to check whether being dyslipidemic or metabolic syndrome shown by the ratio, affects the data of NIHSS results obtained to measure functional outcome. the data was analyzed using Pearson Chi-square with contingency table post-hoc analysis and Spearmann’s Correlation with additional simple-linear regression.Out of 189 subjects, only 156 data are complete and valid. 70 patients were dyslipidemic, 65 were non-dyslipidemic and the rest were unknown. There is a significant association of LDL/HDL ratio cut off point above 2,3 with dyslipidemic drug intake likely to produce a mild NIHSS outcome category (z score 2,1) (calculator is  P value = 0,035729), but not with other NIHSS categories.  There is significant association of patients that do not take dyslipidemic drug with whatever LDL/HDL cut off point to the predictor outcome of Mild NIHSS category, but not with other NIHSS categories. The correlations are also insignificant between the LDL/HDL ratio and NIHSS score in one tailed (p<0,36) and at two tailed (p<0,72).Moreover, simple linear regression reveal that LDL/HDL ratio predicts 16% of NIHSS score, while taking anti dyslipidemic drugs which mean the person is dyslipidemic, and LDL/HDL ratio predict 31% of NIHSS outcome. Therefore LDL/HDL ratio have weak predictor value to NIHSS outcome, should not be an independent predictor.